Original Articles Salvage Chemotherapy, Hodgkin's Disease

Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 2, pp 161-163

VIM-D salvage chemotherapy in Hodgkin's disease

  • Julia K. PhillipsAffiliated withDepartment of Haematology, Royal Liverpool Hospital
  • , Ruth L. SpearingAffiliated withDepartment of Haematology, Royal Liverpool Hospital
  • , John M. DaviesAffiliated withDepartment of Haematology, Royal Liverpool Hospital
  • , Charles R. M. HayAffiliated withDepartment of Haematology, Royal Liverpool Hospital
  • , Huw ParryAffiliated withDepartment of Heamatology, Ysbyty Gwynedd, Penrhosgarnedd
  • , John R. NashAffiliated withDepartment of Histopathology, Royal Liverpool Hospital

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2,4, 10 and 14 months, 10 subjects subsequently received an autologous bone marrow transplant with highdose chemotherapy (ABMT). Previous exposure to VIMD did not appear to predict for or prejudice the response to subsequent ABMT.